FDA Indications: An alternative drug for treatment-resistant depression (not considered a first-line drug of choice) FDA approved for treating major depression mixed anxiety and depression and phobic or hypochondriacal features FDA approved for treating atypical depression (e.g
Gurjar AA, Kushwaha S, Chattopadhyay S, Das N, Pal S, China SP, Kumar H, Trivedi AK, Guha R, Chattopadhyay N, Sanyal S
This approach simplifies the regimen to a single daily injection but limits dosing flexibility
Research shows whether the studies are on metabolic pathways, cellular mechanisms or molecular interactions our SLU-PP-332 and 5-Amino-1MQ compounds meet the specifications for research use
GLP-1 agonists have been studied since the 1970s for a diverse range of functions